Cited by 825Inflammatory Bowel DiseasePsoriasis: Treatment and PathogenesisIL-33, ST2, and ILC Pathways

Interleukin-23 drives innate and T cell–mediated intestinal inflammation

Open access
Hue, Sophie, Ahern, Philip, Buonocore, Sofia, Kullberg, Marika C., Cua, Daniel J., McKenzie, Brent S., Powrie, Fiona, Maloy, Kevin J.·2006·The Journal of Experimental Medicine

Abstract

Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the gastrointestinal tract involving aberrant activation of innate and adaptive immune responses. We have used two complementary models of IBD to examine the roles of interleukin (IL)-12 family cytokines in bacterially induced intestinal inflammation. Our results clearly show that IL-23, but not IL-12, is essential for the induction of chronic intestinal inflammation mediated by innate or adaptive immune mechanisms. Depletion of IL-23 was associated with decreased proinflammatory responses in the intestine but had little impact on systemic T cell inflammatory responses. These results newly identify IL-23 as a driver of innate immune pathology in the intestine and suggest that selective targeting of IL-23 represents an attractive therapeutic approach in human IBD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1084/jem.20061099

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Subsequent studies established an essential role for the IL-23-Th17 axis in disease pathogenesis.

    “whereas subsequent studies established an essential role for the IL-23–Th17 axis in disease pathogenesis (15, 72).”

    From T <sub>H</sub> 17 cells require ongoing classic IL-6 receptor signaling to retain transcriptional and functional identity (2020) · cites this paper as [72]

    The Abstract reports a crucial role for IL-23 in mouse models of intestinal inflammation. The Discussion, however, says IL-23–driven Th17 responses may be important but are one of several mechanisms contributing to colitis; it does not establish that the combined IL-23–Th17 axis is essential. Page numbers are not available in our copy. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [43]Kullberg, M.C., D. Jankovic, C.G. Feng, S. Hue, P.L. Gorelick, B.S. McKenzie, D.J. Cua, F. Powrie, A.W. Cheever, K.J. Maloy, and A. Sher. 2006. IL-23 is a key mediator of Helicobacter hepaticus–induced T cell–dependent colitis. J. Exp. Med. 203: 2485–2494. 17030948 PMC2118119

Cited by

Sorted by citations

Authors
Hue, S., Ahern, P., Buonocore, S., Kullberg, M. C., Cua, D. J., McKenzie, B. S., Powrie, F., & Maloy, K. J.
Affiliations
  • 1Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, England, UK
  • University of Oxford (GB)
  • University of York (GB)
  • 3Department of Discovery Research, Schering-Plough Biopharma, Palo Alto, CA 94304
Venue
The Journal of Experimental Medicine
Published
2006-10-09
Volume
203
Issue
11
Pages
2473-2483
ISSN
  • 0022-1007 (ISSN-L)
  • 1540-9538
OpenAlex
W2133765154
Cited by
823
References
61
Citations by year
2026: 9 · 2025: 15 · 2024: 19 · 2023: 18 · 2022: 18 · 2021: 23 · 2020: 22 · 2019: 45 · 2018: 33 · 2017: 29 · 2016: 36 · 2015: 29 · 2014: 46 · 2013: 50 · 2012: 49
FWCI
47.65
Type
journal article
Language
en
Open access
Locations
  • The Journal of Experimental Medicine (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
  • PubMed Central (publishedVersion, cc-by-nc-sa)
  • PubMed (publishedVersion)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-sa)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
Funders
  • Wellcome Trust (070361)
  • University of Oxford
  • European Commission
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Inflammatory Bowel Disease
  • Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
  • Life Sciences › Immunology and Microbiology › Immunology › IL-33, ST2, and ILC Pathways
Keywords
IL-23, IL-12, inflammatory bowel disease, intestinal inflammation, innate immunity, T cell-mediated inflammation
MeSH terms
Animals, Immunity, Innate, Mice, Inbred C57BL, T-Lymphocytes, Inflammatory Bowel Diseases, Helicobacter Infections, Mice, Knockout, Helicobacter hepaticus, Mice, Interleukin-23

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review